Unityca Tablets 60 Milligrams (Ticagrelor)

Adult dose

Do not use this medicine concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg per dose twice daily. Treatment for 12 months is recommended unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg per dose twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who were taking 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg per dose twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration instructions. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg per dose twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink the mixture. Rinse the glass used for administration with half a glass of water and drink again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy in pediatric patients younger than 18 years have not been established (see the 'Other' section).

This drug is used to prevent platelets from clumping together to form clots, thus reducing the risk of cardiovascular diseases such as myocardial infarction or stroke. However, this drug may increase the risk of bleeding, and should not be used in patients with current bleeding or a history of intracranial hemorrhage. If surgery is planned, the use of this drug should be discontinued at least 5 days prior to the procedure, and any signs of bleeding should be reported to medical personnel immediately. This drug may have increased side effects when taken by patients with severely impaired liver function or in combination with certain antibiotics and antiviral agents, and should be avoided. Patients with a high risk of bleeding, those who have recently experienced trauma or surgery, or those with blood coagulation disorders should use this drug cautiously, particularly when used in conjunction with other anticoagulants. During the use of this drug, unusual symptoms such as dyspnea, bradycardia (slowed heart rate), headache, dizziness, and bleeding may occur; if such symptoms arise, you should consult your doctor immediately. Pregnant or breastfeeding women are advised to avoid using this drug, and women of childbearing potential should use appropriate contraception to avoid pregnancy while taking this drug. The safety and efficacy of this drug in children have not been established, and it is not recommended for use in this population. Elderly patients may use it without special dosage adjustments, but regular monitoring of kidney function is advised. In case of overdose, the risk of bleeding increases, and currently, there is no specific antidote to reverse this drug; therefore, immediate treatment should be sought if symptoms of bleeding occur. This drug may interact with other medications; therefore, you should inform your healthcare provider of any other medications you are taking, particularly simvastatin, digoxin, or cyclosporine. Caution should be exercised when driving or operating machinery as dizziness or confusion may occur during treatment. This drug should be stored in its original container and kept out of the reach of children.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• difficulty breathing
• respiratory tract hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

This drug may be sensitive to air or moisture, so it should be stored in a sealed container. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius room temperature. This way, the drug's effectiveness and safety can be maintained for a longer time.

Appearance

Pink, double-sided, convex round film-coated tablets

Package unit

56 tablets/box [(14 tablets PTP X4)]